|
시장보고서
상품코드
1786995
세계의 비호지킨 림프종 치료제 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 세포 유형별, 치료 유형별, 투여 경로별, 지역별 예측(2025-2034년)Non-Hodgkin Lymphoma Therapeutics Market Size, Share, Trends, & Industry Analysis Report By Cell Type (B-cell lymphomas, T-cell lymphoma),By Therapy Type, By Route of Administration, and By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최근 조사에 따르면 세계의 비호지킨 림프종 치료제 시장 규모는 2034년까지 189억 달러에 이를 것으로 예측됩니다. 이 조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.
비호지킨 림프종 치료제는 효능, 안전성 및 환자 생존 기간의 연장에 초점을 맞추어 다양한 림프계 암의 아형을 다루도록 설계된 광범위한 표적 치료를 지칭합니다. 이러한 치료제는 정확성, 일관성 및 양호한 치료 효과를 보장하기 위해 엄격한 임상 기준 하에서 개발되었습니다.
시장의 성장에는 세계의 암 이환율 증가와 안전성 프로파일을 개선한 효과적인 표적 치료제에 대한 긴급한 요구가 박차를 가하고 있습니다. 암 면역요법, 단일클론항체, CAR-T 세포 치료의 진보는 재발난치성 비호지킨 림프종의 임상 결과를 향상시키고 있습니다. 헬스케어 투자 증가와 규제 당국의 지원책에 의해 세계의 주요 치료 센터에서 차세대 림프종 치료제의 개발과 이용이 더욱 가속화되고 있습니다.
비호지킨 림프종 치료제 시장 보고서 하이라이트
세포 유형별로, B 세포 림프종 부문은 2024년 시장에서 가장 큰 점유율을 차지했습니다. 이는 B 세포 림프종의 유병률이 높고 관해율과 장기 생존율을 향상시키는 표적 치료 옵션의 이용 가능성이 높아지고 있기 때문입니다.
치료법 유형별로 보면, 표적 요법은 건강한 조직에 대한 손상을 최소화하면서 암세포를 정확하게 공격하기 때문에 급성장이 예상되고 있습니다.
투여 경로별로, 병원과 종양 센터에서 널리 사용되는 정맥내 투여는 2024년 시장 점유율을 독점하여 투여량과 효능을 조절하면서 생물학적 제제 및 화학요법을 투여하기 위해 사용되었습니다.
북미는 2024년에 세계의 비호지킨 림프종 치료제 시장에서 가장 큰 점유율을 차지했으며, 이는 왕성한 건강 관리 지출과 림프종 치료제 개발에 종사하는 주요 바이오 제약 기업의 존재에 밀려 온 것입니다.
아시아태평양은 암 부담 증가와 첨단 치료 접근성 증가로 예측 기간 동안 시장 점유율이 크게 CAGR로 성장할 것으로 예측됩니다.
세계 주요 시장 기업은 AbbVie Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Janssen Biotech, Inc., Teva Pharmaceutical Industries Ltd., Verismo Therapeutics 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 비호지킨 림프종 치료제 시장 인사이트
- 시장 현황
- 비호지킨 림프종 치료제 시장 역학
- 성장 촉진요인과 기회
- 정부의 의료비 지출 증가
- 세계에서 NHL 증례가 증가
- 억제요인과 과제
- 고액의 치료비
- 성장 촉진요인과 기회
- PESTEL 분석
- 비호지킨 림프종 치료제 시장 동향
- 밸류체인 분석
제5장 세계의 비호지킨 림프종 치료제 시장 : 세포 유형별
- 주요 조사 결과
- 소개
- B세포 림프종
- T세포 림프종
제6장 세계의 비호지킨 림프종 치료제 시장 : 치료 유형별
- 주요 조사 결과
- 소개
- 화학요법
- 표적요법
- 방사선치료
- 기타 치료법
제7장 세계의 비호지킨 림프종 치료제 시장 : 투여 경로별
- 주요 조사 결과
- 소개
- 경구
- 정맥내
- 피하
제8장 세계의 비호지킨 림프종 치료제 시장 : 지역별
- 주요 조사 결과
- 소개
- 비호지킨 림프종 치료제 시장 분석 : 지역별, 2020-2034년
- 북미
- 북미 : 세포 유형별, 2020-2034년
- 북미 : 치료 유형별, 2020-2034년
- 북미 : 투여 경로별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 세포 유형별, 2020-2034년
- 유럽 : 치료 유형별, 2020-2034년
- 유럽 : 투여 경로별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 세포 유형별, 2020-2034년
- 아시아태평양 : 치료 유형별, 2020-2034년
- 아시아태평양 : 투여 경로별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 세포 유형별, 2020-2034년
- 중동 및 아프리카 : 치료 유형별, 2020-2034년
- 중동 및 아프리카 : 투여 경로별, 2020-2034년
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 세포 유형별, 2020-2034년
- 라틴아메리카 : 치료 유형별, 2020-2034년
- 라틴아메리카 : 투여 경로별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제9장 경쟁 구도
- 확대 및 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제10장 기업 프로파일
- AbbVie Inc.
- AstraZeneca PLC
- Baxter International Inc.
- Bayer AG
- Bristol Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann La-Roche Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- Janssen Biotech, Inc.
- Teva Pharmaceutical Industries Ltd.
- Verismo Therapeutics, Inc.
The Non-Hodgkin lymphoma therapeutics market size is expected to reach USD 18.90 Billion by 2034, according to a new study by Polaris Market Research. The report "Non-Hodgkin Lymphoma Therapeutics Market Share, Size, Trends, Industry Analysis Report: By Cell Type (B-cell lymphomas, T-cell lymphoma), By Therapy Type, By Route of Administration, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Non-Hodgkin lymphoma therapeutics refer to a broad spectrum of targeted treatments designed to address diverse lymphatic cancer subtypes, focusing on efficacy, safety, and prolonged patient survival. These therapies are developed under stringent clinical standards to ensure precision, consistency, and favorable treatment response.
The market growth is fueled by increasing global cancer incidence and the urgent need for effective targeted therapies with improved safety profiles. Advancements in cancer immunotherapy, monoclonal antibodies, and CAR-T cell treatments are enhancing clinical outcomes for relapsed and refractory NHL cases. Rising healthcare investments and supportive regulatory pathways are further accelerating the development and accessibility of next-generation lymphoma therapeutics across major treatment centers worldwide.
Non-Hodgkin Lymphoma Therapeutics Market Report Highlights
Based on cell type, the B-cell lymphoma segment held largest share of the market in 2024, due to its high prevalence and growing availability of targeted treatment options that improve remission rates and long-term survival outcomes.
Based on therapy type, the targeted therapy segment is expected to witness the fastest growth, due to its precision in attacking cancerous cells while minimizing damage to healthy tissue
Based on route of administration, the intravenous segment held the dominant market share in 2024, driven by the widespread use in hospitals and oncology centers for delivering biologics and chemotherapy with controlled dosage and efficacy.
North America accounted for largest share of the global non-hodgkin lymphoma therapeutics market in 2024, fueled by strong healthcare spending and the presence of leading biopharmaceutical companies engaged in lymphoma drug development.
Asia Pacific is expected to grow with a significant CAGR during the forecast period market share, due to the growing cancer burden and increased access to advanced therapies.
A few global key market players include AbbVie Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Janssen Biotech, Inc., Teva Pharmaceutical Industries Ltd., and Verismo Therapeutics, Inc.
Polaris Market Research has segmented the market report on the basis of cell type, therapy type, route of administration, and region:
By Cell Type Outlook (Revenue, USD Billion, 2020-2034)
B-cell lymphomas
T-cell lymphoma
By Therapy Type Outlook (Revenue, USD Billion, 2020-2034)
Chemotherapy
Targeted therapy
Radiation therapy
Other therapy types
By Route of Administration (Revenue, USD Billion, 2020-2034)
Oral
Intravenous
Subcutaneous
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Non-Hodgkin Lymphoma Therapeutics Market Insights
- 4.1. Non-Hodgkin Lymphoma Therapeutics Market - Market Snapshot
- 4.2. Non-Hodgkin Lymphoma Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Government Healthcare Spending
- 4.2.1.2. Rising Cases of NHL Worldwide
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Treatment Costs
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Non-Hodgkin Lymphoma Therapeutics Market Trends
- 4.6. Value Chain Analysis
5. Global Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 5.3. B-cell lymphomas
- 5.3.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by B-cell lymphomas, by Region, 2020-2034 (USD Billion)
- 5.4. T-cell lymphomas
- 5.4.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by T-cell lymphomas, by Region, 2020-2034 (USD Billion)
6. Global Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 6.3. Chemotherapy
- 6.3.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
- 6.4. Targeted Therapy
- 6.4.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
- 6.5. Radiation Therapy
- 6.5.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Radiation Therapy, by Region, 2020-2034 (USD Billion)
- 6.6. Other Therapy Types
- 6.6.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Other Therapy Types, by Region, 2020-2034 (USD Billion)
7. Global Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 7.3. Oral
- 7.3.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Oral, by Region, 2020-2034 (USD Billion)
- 7.4. Intravenous
- 7.4.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Intravenous, by Region, 2020-2034 (USD Billion)
- 7.5. Subcutaneous
- 7.5.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Subcutaneous, by Region, 2020-2034 (USD Billion)
8. Global Non-Hodgkin Lymphoma Therapeutics Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Non-Hodgkin Lymphoma Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
- 8.3. Non-Hodgkin Lymphoma Therapeutics Market - North America
- 8.3.1. North America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.3.2. North America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.3.3. North America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.3.4. Non-Hodgkin Lymphoma Therapeutics Market - US
- 8.3.4.1. US: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.3.4.2. US: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.3.4.3. US: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.3.5. Non-Hodgkin Lymphoma Therapeutics Market - Canada
- 8.3.5.1. Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.3.5.2. Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.3.5.3. Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.4. Non-Hodgkin Lymphoma Therapeutics Market - Europe
- 8.4.1. Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.4.2. Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.4.3. Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.4.4. Non-Hodgkin Lymphoma Therapeutics Market - UK
- 8.4.4.1. UK: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.4.4.2. UK: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.4.4.3. UK: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.4.5. Non-Hodgkin Lymphoma Therapeutics Market - France
- 8.4.5.1. France: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.4.5.2. France: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.4.5.3. France: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.4.6. Non-Hodgkin Lymphoma Therapeutics Market - Germany
- 8.4.6.1. Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.4.6.2. Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.4.6.3. Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.4.7. Non-Hodgkin Lymphoma Therapeutics Market - Italy
- 8.4.7.1. Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.4.7.2. Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.4.7.3. Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.4.8. Non-Hodgkin Lymphoma Therapeutics Market - Spain
- 8.4.8.1. Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.4.8.2. Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.4.8.3. Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.4.9. Non-Hodgkin Lymphoma Therapeutics Market - Netherlands
- 8.4.9.1. Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.4.9.2. Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.4.9.3. Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.4.10. Non-Hodgkin Lymphoma Therapeutics Market - Russia
- 8.4.10.1. Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.4.10.2. Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.4.10.3. Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.4.11. Non-Hodgkin Lymphoma Therapeutics Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.4.11.2. Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.4.11.3. Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.5. Non-Hodgkin Lymphoma Therapeutics Market - Asia Pacific
- 8.5.1. Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.5.4. Non-Hodgkin Lymphoma Therapeutics Market - China
- 8.5.4.1. China: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.5.4.2. China: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.5.4.3. China: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.5.5. Non-Hodgkin Lymphoma Therapeutics Market - India
- 8.5.5.1. India: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.5.5.2. India: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.5.5.3. India: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.5.6. Non-Hodgkin Lymphoma Therapeutics Market - Malaysia
- 8.5.6.1. Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.5.6.2. Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.5.6.3. Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.5.7. Non-Hodgkin Lymphoma Therapeutics Market - Japan
- 8.5.7.1. Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.5.7.2. Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.5.7.3. Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.5.8. Non-Hodgkin Lymphoma Therapeutics Market - Indonesia
- 8.5.8.1. Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.5.8.2. Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.5.8.3. Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.5.9. Non-Hodgkin Lymphoma Therapeutics Market - South Korea
- 8.5.9.1. South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.5.9.2. South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.5.9.3. South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.5.10. Non-Hodgkin Lymphoma Therapeutics Market - Australia
- 8.5.10.1. Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.5.10.2. Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.5.10.3. Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.5.11. Non-Hodgkin Lymphoma Therapeutics Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.5.11.2. Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.5.11.3. Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.6. Non-Hodgkin Lymphoma Therapeutics Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.6.4. Non-Hodgkin Lymphoma Therapeutics Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.6.4.2. Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.6.4.3. Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.6.5. Non-Hodgkin Lymphoma Therapeutics Market - UAE
- 8.6.5.1. UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.6.5.2. UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.6.5.3. UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.6.6. Non-Hodgkin Lymphoma Therapeutics Market - Israel
- 8.6.6.1. Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.6.6.2. Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.6.6.3. Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.6.7. Non-Hodgkin Lymphoma Therapeutics Market - South Africa
- 8.6.7.1. South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.6.7.2. South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.6.7.3. South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.6.8. Non-Hodgkin Lymphoma Therapeutics Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.6.8.2. Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.6.8.3. Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.7. Non-Hodgkin Lymphoma Therapeutics Market - Latin America
- 8.7.1. Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.7.4. Non-Hodgkin Lymphoma Therapeutics Market - Mexico
- 8.7.4.1. Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.7.4.2. Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.7.4.3. Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.7.5. Non-Hodgkin Lymphoma Therapeutics Market - Brazil
- 8.7.5.1. Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.7.5.2. Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.7.5.3. Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.7.6. Non-Hodgkin Lymphoma Therapeutics Market - Argentina
- 8.7.6.1. Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.7.6.2. Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.7.6.3. Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.7.7. Non-Hodgkin Lymphoma Therapeutics Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
- 8.7.7.2. Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
- 8.7.7.3. Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. AbbVie Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Cell Type Benchmarking
- 10.1.4. Recent Development
- 10.2. AstraZeneca PLC
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Cell Type Benchmarking
- 10.2.4. Recent Development
- 10.3. Baxter International Inc.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Cell Type Benchmarking
- 10.3.4. Recent Development
- 10.4. Bayer AG
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Cell Type Benchmarking
- 10.4.4. Recent Development
- 10.5. Bristol Myers Squibb Company
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Cell Type Benchmarking
- 10.5.4. Recent Development
- 10.6. Eli Lilly and Company
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Cell Type Benchmarking
- 10.6.4. Recent Development
- 10.7. F. Hoffmann La-Roche Ltd.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Cell Type Benchmarking
- 10.7.4. Recent Development
- 10.8. Gilead Sciences, Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Cell Type Benchmarking
- 10.8.4. Recent Development
- 10.9. GlaxoSmithKline PLC
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Cell Type Benchmarking
- 10.9.4. Recent Development
- 10.10. Janssen Biotech, Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Cell Type Benchmarking
- 10.10.4. Recent Development
- 10.11. Teva Pharmaceutical Industries Ltd.
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Cell Type Benchmarking
- 10.11.4. Recent Development
- 10.12. Verismo Therapeutics, Inc.
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Cell Type Benchmarking
- 10.12.4. Recent Development
